Compile Data Set for Download or QSAR
Report error Found 700 for UniProtKB: P26010
TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM50535742(CHEMBL4592659)
Affinity DataEC50:  1.40nMAssay Description:Antagonist activity at integrin alpha4beta7 expressed in human RPMI8866 cells assessed as reduction in cell adhesion to rat MadCAM incubated for 40 t...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
LigandPNGBDBM260669(US9533985, 57)
Affinity DataIC50: 0.0600nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260666(US9533985, 54)
Affinity DataIC50: 0.0770nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260683(US9533985, 71)
Affinity DataIC50: 0.0980nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260680(US9533985, 68)
Affinity DataIC50: 0.130nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260671(US9533985, 59)
Affinity DataIC50: 0.170nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260681(US9533985, 69)
Affinity DataIC50: 0.210nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260660(US9533985, 48)
Affinity DataIC50: 0.240nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260653(US9533985, 41)
Affinity DataIC50: 0.260nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260667(US9533985, 55)
Affinity DataIC50: 0.270nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260654(US9533985, 42)
Affinity DataIC50: 0.270nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260689(US9533985, 77)
Affinity DataIC50: 0.270nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314067(US9610264, Compound 4)
Affinity DataIC50: 0.270nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260659(US9533985, 47)
Affinity DataIC50: 0.320nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260662(US9533985, 50)
Affinity DataIC50: 0.320nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314059(US9610264, Compound 1)
Affinity DataIC50: 0.330nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260687(US9533985, 75)
Affinity DataIC50: 0.380nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260686(US9533985, 74)
Affinity DataIC50: 0.390nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260682(US9533985, 70)
Affinity DataIC50: 0.410nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260661(US9533985, 49)
Affinity DataIC50: 0.430nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMucosal addressin cell adhesion molecule 1/Integrin alpha-4/beta-7(Human)
Hangzhou Apeloa Medicine Research Institute Co.

US Patent
LigandPNGBDBM672866(US20240150287, Example 35 | (S)-3-(4-(7-methoxy-3-...)
Affinity DataIC50: 0.450nMAssay Description:Coat the 96-well microplate (Costar) with 50 μL of recombinant human MAdCAM-1 (R&D Systems) solution per well, and incubate overnight (12-18 hou...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260673(US9533985, 61)
Affinity DataIC50: 0.460nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314070(US9610264, Compound 6)
Affinity DataIC50: 0.460nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260679(US9533985, 67)
Affinity DataIC50: 0.550nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260677(US9533985, 65)
Affinity DataIC50: 0.560nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM16839((2S)-3-{4-[(3,5-dichloropyridine-4-)amido]phenyl}-...)
Affinity DataIC50: 0.600nMT: 2°CAssay Description: Immulon 96-well plates were coated with recombinant hVCAM-1 overnight at 4 C. Plates were washed and blocked for 1 h at room temperature in PBS-BSA....More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314068(US9610264, Compound 5)
Affinity DataIC50: 0.610nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260656(US9533985, 44)
Affinity DataIC50: 0.620nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260674(US9533985, 62)
Affinity DataIC50: 0.640nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314068(US9610264, Compound 5)
Affinity DataIC50: 0.640nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260683(US9533985, 71)
Affinity DataIC50: 0.720nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM65394(US9533985, 159 | US9533985, 40)
Affinity DataIC50: 0.730nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM16801(CHEMBL91485 | N-Acyl-4-arylphenylalanine analogue....)
Affinity DataIC50: 0.75nMAssay Description:Inhibition of [125I]MAdCAM-Ig binding to alpha4-beta7 integrin of human RPMI-8866 cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetMucosal addressin cell adhesion molecule 1/Integrin alpha-4/beta-7(Human)
Hangzhou Apeloa Medicine Research Institute Co.

US Patent
LigandPNGBDBM672848(US20240150287, Example 16 | (S)-3-(4-(2′-oxo...)
Affinity DataIC50: 0.75nMAssay Description:Coat the 96-well microplate (Costar) with 50 μL of recombinant human MAdCAM-1 (R&D Systems) solution per well, and incubate overnight (12-18 hou...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260690(US9533985, 78)
Affinity DataIC50: 0.790nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260675(US9533985, 63)
Affinity DataIC50: 0.800nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260651(US9533985, 39)
Affinity DataIC50: 0.830nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314065(US9610264, Compound 2)
Affinity DataIC50: 0.890nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260655(US9533985, 43)
Affinity DataIC50: 0.900nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260685(US9533985, 73)
Affinity DataIC50: 0.950nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM65383(BDBM260657 | US9533985, 157)
Affinity DataIC50: 0.970nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314071(US9610264, Compound 7)
Affinity DataIC50: 0.980nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260670(US9533985, 58)
Affinity DataIC50: 1nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260658(US9533985, 46)
Affinity DataIC50: 1.10nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260672(US9533985, 60)
Affinity DataIC50: 1.10nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMucosal addressin cell adhesion molecule 1/Integrin alpha-4/beta-7(Human)
Hangzhou Apeloa Medicine Research Institute Co.

US Patent
LigandPNGBDBM672853(US20240150287, Example 22 | (S)-3-(4-(7-chloro-3-m...)
Affinity DataIC50: 1.19nMAssay Description:Coat the 96-well microplate (Costar) with 50 μL of recombinant human MAdCAM-1 (R&D Systems) solution per well, and incubate overnight (12-18 hou...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetIntegrin alpha-4/beta-7(Human)
Gilead Sciences

Curated by ChEMBL
LigandPNGBDBM314072(US9610264, Compound 8)
Affinity DataIC50: 1.23nMAssay Description:The studies began by screening for the optimal protein concentrations for the method. The studies were conducted in goat anti-mouse IgG coated black ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260681(US9533985, 69)
Affinity DataIC50: 1.30nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM260669(US9533985, 57)
Affinity DataIC50: 1.5nMpH: 9.6 T: 2°CAssay Description:The ability of test substances to inhibit the binding of a human B cell line, RPMI-8866, which is known to express α4β7 integrin, to MAdCA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetMucosal addressin cell adhesion molecule 1/Integrin alpha-4/beta-7(Human)
Hangzhou Apeloa Medicine Research Institute Co.

US Patent
LigandPNGBDBM672867(US20240150287, Example 36 | (S)-3-(4-(6-(dimethyla...)
Affinity DataIC50: 1.51nMAssay Description:Coat the 96-well microplate (Costar) with 50 μL of recombinant human MAdCAM-1 (R&D Systems) solution per well, and incubate overnight (12-18 hou...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 700 total ) | Next | Last >>
Jump to: